MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 1

Conditions

Advanced Solid Tumors

Colorectal Cancer

Treatments

Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00099346

MK0457-001

0457-001

2004_095

Details and patient eligibility

About

Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

In Part I, patients who are at least 18 years of age with advanced solid tumors and colorectal cancer will be eligible for the first part of this study. Patient must have recovered from and be at least 3 weeks from previous cancer treatment.
In Part II, only patients with colorectal cancer will be eligible to participate. The patients may have received up to 3 prior treatments for their colorectal cancer. Patients must have recovered from and be at least 3 weeks from previous therapy.

Exclusion criteria

Patients who have had treatment with any investigational drug within the past 30 days.
Patients who have certain types of blood cancers such as leukemia or lymphoma.
Patients who have uncontrolled congestive heart failure (CHF), chest pain, or heart attack within the past 3 months.
Patient is pregnant or nursing.